Fractional Flow Reserve: Clinical Trials Update
|
|
- Linette Osborne
- 6 years ago
- Views:
Transcription
1 3/22/2013 Fractional Flow Reserve: Clinical Trials Update William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research support from St. Jude Medical Research and salary support from National Institutes of Health: 1 R01 HL (PI) FFR: Gold Standard for Identifying Ischemia Proximal Pressure (Pa) Distal Pressure (Pd) FFR = P d / P a during maximal flow P a P d / P a = 60 / 100 FFR = 0.60 P d 1
2 3/22/2013 Validation of FFR Fractional Flow Reserve Exercise Test Thallium Scan Stress Echo 0.75 FFR < 0.75 : Sensitivity = 88% Specificity = 100% Pijls et al., New Engl J Med 1996;334:1703 What is FAME 1? Fractional Flow Reserve versus Angiography for Multivessel Evaluation Tonino, et al. New Engl J Med 2009;360: FAME 1 Trial: FFR-Guided PCI performed on indicated lesions only if FFR 0.80 Lesions warranting PCI identified Randomized Angio-Guided PCI performed on indicated lesions Primary Endpoint Composite of death, MI and repeat revasc. (MACE) at 1 year Tonino, et al. New Engl J Med 2009;360:
3 3/22/2013 Angio- Guided n = 496 FFR- Guided n = 509 P Value Indicated lesions / patient 2.7± ± Stents / patient 2.7 ± ± 1.3 <0.001 Angio- Guided n = 496 FFR- Guided n = 509 P Value Indicated lesions / patient 2.7± ± Stents / patient 2.7 ± ± 1.3 <0.001 Procedure time (min) 70 ± ± Contrast agent used (ml) 302 ± ± 133 <0.001 Equipment cost (US $) <0.001 Length of hospital stay (days) 3.7 ± ± FAME Study: One Year Outcomes % 20 Angio-Guided FFR-Guided ~30% ~40% ~35% ~30% ~35% Death MI Repeat Revasc Death/MI p=0.04 MACE p=0.02 Tonino, et al. New Engl J Med 2009;360:
4 3/22/2013 FAME: Economic Evaluation Bootstrap Analysis FFR-guided PCI saved >$2,000 per patient at one year compared to Angioguided PCI Circulation 2010;122: FAME Study: Two Year Outcomes Death/MI was significantly reduced from 12.9% to 8.4% (p=0.02) Survival Free of MACE FFR-Guided Angio-Guided 730 days 4.5% Pijls, et al. J Am Coll Cardiol 2010;56: Functional SYNTAX Score Reclassifies > 30% of Cases Without FFR Nam CW, et al. J Am Coll Cardiol 2011;58:
5 3/22/2013 Functional SYNTAX Score Reclassifies > 30% of Cases Without FFR With FFR Nam CW, et al. J Am Coll Cardiol 2011;58: Functional SYNTAX Score Discriminates Risk for Death/MI P < % 32% 34% 59% Nam CW, et al. J Am Coll Cardiol 2011;58: Implications of FAME Death and MI in the COURAGE study FAME 2 Boden et al., New Engl J Med 2007;356:
6 3/22/2013 FAME 2 Stable CAD patients scheduled for 1, 2 or 3 vessel DES-PCI N = 1220 Randomized Trial FFR in all target lesions Registry At least 1 stenosis with FFR 0.80 (n=888) When all FFR > 0.80 (n=332) Randomization 1:1 PCI + MT 73% MT 27% MT 50% randomly assigned to FU Primary Endpoint: Death, MI or urgent revascularization at 2 Yr 69 yo man with chest pain and apical ischemia on NPS FFR of RCA =
7 3/22/2013 FFR of LAD = 0.51 LAD after PCI Baseline Characteristics Randomized Trial Registry p Patients, N PCI+MT=447 MT=441 with FU=166 Demographic Age (y) 63.5± ± ± Male sex - (%) BMI 28.3± ± ± Risk factors for CAD Positive family history CAD - (%) Smoking - (%) Hypertension - (%) Hypercholesterolemia - (%) Diabetes mellitus - (%) Insulin requiring diabetes - (%) De Bruyne, et al. New Engl J Med 2012;367:
8 Cumulative incidence (%) 3/22/2013 Angiographic Characteristics Randomized trial N=888 Registry N=322 Patients, N PCI+MT=447 MT=441 with FU=166 P* Angiographically significant stenoses - no. per patient 1.87± ± ±0.59 <0.001 No of vessels with 1 significant stenoses - (%) <0.001 Prox- or mid- LAD stenoses - (%) <0.001 De Bruyne, et al. New Engl J Med 2012;367: Patients with Angina Class II to IV % p<0.001 p=0.002 De Bruyne, et al. New Engl J Med 2012;367: Primary Endpoint: Death, MI, Urgent Revasc 30 PCI+MT vs. MT: HR 0.32 ( ); p<0.001 PCI+MT vs. Registry: HR 1.29 ( ); p= MT vs. Registry: HR 4.32 ( ); p< No. at risk MT PCI+MT Registry Months after randomization
9 Cumulative incidence (%) Cumulative (%) 3/22/2013 Landmark Analysis of Death or MI days: HR 7.99 ( ); p=0.038 > 8 days: HR 0.42 ( ); p=0.053 p-interaction: p= Days after randomization >8 days PCI plus MT MT alone 7 days 07days Months after randomization MT alone PCI plus MT Patients with urgent revascularization 21.4% Myocardial Infarction 51.8% 26.8% Unstable angina +evidence of ischemia on ECG Patients with urgent revascularization Urgent revascularization driven by MI or unstable angina with ECG changes FFR-Guided PCI + MT 51.8% MT 0.9% vs. 5.2% p< % Relative Risk Reduction 21.4% 26.8% Myocardial Infarction Unstable angina +evidence of ischemia on ECG 9
10 3/22/2013 Cost-Effectiveness in FAME 2 Cumulative Costs during first 12 months $2,508 $5,485 Late Breaking Trial: TCT 2012 Cost-Effectiveness of FAME-2 Quality of Life at 1 Month Angina (%) FFR-Guided PCI MT p-value Class <0.001 Class <0.001 Utility Change <0.001 Late Breaking Trial: TCT 2012 Cost-Effectiveness of FAME-2 In-trial results $2,500 / QALY = $53,000 / QALY Three Year Projection $2,500 / QALY = $32,000 / QALY Late Breaking Trial: TCT
11 3/22/2013 Conclusions FFR-Guide PCI improves outcomes and saves resources compared to angio-guided PCI in stable and unstable patients with multivessel CAD. In patients with stable coronary artery disease, FFR-guided PCI improves patient outcome as compared with medical therapy alone. In patients with functionally non-significant stenoses, medical therapy alone resulted in an excellent outcome, regardless of the angiographic appearance of the stenoses. 11
12 Time to to Retool Your Interventions 3/25/2013 Use of I.V.U.S. and F.F.R. in the Treatment of Complex Multivessel Coronary Artery Disease David G. Rizik, M.D., F.A.C.C. Director of Heart & Vascular Medicine Scottsdale Heart Group at Scottsdale Healthcare Hospitals Disclosure Cordis Scientific Advisory Panel Abbott Medical Advisory Board Boston Scientific: Research Support TherOx Scientific Panel InfraRed X Advisory Panel TriReme Medical Scientific Advisory Board IVUS and FFR Use of IVUS. Applying those lessons learned from use of IVUS. Applying FFR in complex decision making. 1
13 3/25/2013 Acute MI in the Setting of Multi-Vessel CAD 66 year non-diabetic with a history of hypertension, hypercholesterolemia and a family of CAD. He presented with his first episode of chest pain to the ER. As he was naïve to DAPT, he received loading doses ASA and a thienopyridine in the ER 2
14 3/25/2013 Lessons Learned From Use Of IVUS 2.5 Balloon for Initial Dilation of the RCA 3
15 3/25/ Xience Stent Following Implantation of a 3.0 Stent 4
16 3/25/ NC Balloon at 20 atm Use of IVUS 5
17 3/25/2013 Double Wire 2.5 MB Balloon, 2.0 SB Balloon 6
18 3/25/ MB Baloon, 2.25 SB Stent 3.0 MB Xience Stent x 2 Final Result??? 7
19 3/25/2013 What Did We Learn in This Case From Utilizing IVUS MB Stent grossly undersized. SB Stent grossly undersized Residual disease in SB ostium mandates both MB and SB direct IVUS imaging 2.5 NC SB, 4.0 NC MB 8
20 3/25/2013 Three Studies Have Suggested that Patients with Bifurcation Lesions Treated with IVUS Guidance Do Better Long-term than Patients with Bifurcation Lesions Treated with Angiographic Guidance Kim et al. Am Heart J 2011;161:180-7 Bifurcation lesions, propensity score matching (n=487 in each group) Kim et al. Am J Cardiol 2010;106:612-8 Bifurcation lesions, propensity score matching (n=303 / n=111) Patel et al. Am J Cardiol, Bifurcation lesions, propensity score matching (n=247 / n=202) Incomplete Crush Apposition Optimal Imaging techniques MV MV Incomplete crushing incomplete apposition of the SB or MV stent struts against the MV wall proximal to the carina was found in >60% of non-lm lesions Costa et al. J Am Coll Cardiol. 2005;46: Serial IVUS (post-intervention and follow-up) analysis of the main and side-branches in 73 bifurcation lesions treated with T-stenting Stent expansion was significantly less in the SB than in the MV (87.1±20.4% vs. 97.0±29.1%, p=0.007). The SB ostium was the most frequent site of the post-procedural MSA. At the SB ostium, follow-up MLA correlated with post-procedural MSA (r=0.805, p <0.001). The percentage of neointimal area was higher at the SB ostium than at the MV proximal, MV distal, and SB distal stent (p<0.0001). Hahn et al. J Am Coll Cardiol 2009;54:
21 3/25/2013 Percentage of Neointimal Hyperplasia in the Sidebranch and Main Vessel %IH Hahn et al. J Am Coll Cardiol 2009;54:110-7 An important Principle of IVUS Imaging Image Both Parent & Daughter Vessel Definitive IVUS study of bifurcation lesions EEM and lumen areas, remodeling, and plaque burden requires direct imaging of the both the main branch to the main vessel as well as the side branch to the main vessel. IVUS imaging of only the main branch of the main vessel is, at best, inferential and at worst misleading. Most of the available IVUS data is from LMCA and LAD/D1 bifurcations. Gary Mintz Personal Communication October 2012 LAD LAD 10
22 3/25/2013 Diagonal Tangential Imaging Direct Imaging Diagonal n=471 89% Medina Class 1,1,1 A wide variety of stenting techniques were used. Clinical outcomes: death, myocardial infarction (MI), periprocedural MI, stent thrombosis, target vessel revascularization (TVR), and target lesion revascularization (TLR) were compared between patients undergoing PCI with and without IVUS. Use of IVUS was associated with significantly lower rates death and/or MI, periprocedural MI and TLR-TVR compared to no IVUS use. In addition, 50% of the time IVUS led the interventionalist to modify his treatment strategy 11
23 3/25/2013 Current Medical Therapy DAPT Oral nitrates ARB Beta-Blockers Statin therapy Staging of LAD Use of IVUS and FFR 12
24 3/25/2013 FFR of the LAD 0.61 Double Wire IVUS Pre-Procedure 13
25 3/25/2013 IVUS Pre Intervention Proximal LAD Disease 14
26 3/25/2013 IVUS Confirms Length of Lesion in MB IVUS Post PCI of the LAD MB Intervention Complete What About SB Ostium? 15
27 3/25/2013 Utilizing FFR for Assessment of the S.B. Physiologic Assessment of Jailed Side Branch Lesions Using Fractional Flow Reserve 97 jailed side branch lesions (vessel size >2.0 mm, percent stenosis >50% by visual estimation) after stent implantation at main branches were consecutively enrolled. FFR was measured using a pressure wire at 5 mm distal and proximal to the ostial lesion of the jailed side branch. FFR measurement was successful in 94 lesions. Koo et al. JACC Vol. 46, No. 4, 2005 Utilizing FFR for Assessment of the S.B. Physiologic Assessment of Jailed Side Branch Lesions Using Fractional Flow Reserve 78% of the lesions were located in the diagonal branches Mean percent stenosis 79+11% Reference vessel diameter mm Lesion length of jailed SB mm Mean FFR in jailed SB (after intracoronary 80-g bolus adenosine administration and with 240-g/min adenosine continuous Infusion) Koo et al. JACC Vol. 46, No. 4, 2005 Utilizing FFR for Assessment of the S.B. Physiologic Assessment of Jailed Side Branch Lesions Using Fractional Flow Reserve Among 73 lesions with >75% stenosis, only 20 lesions (27%) had functionally significant stenosis (by FFR). In relatively large side branches (>2.5 mm) with >75% stenosis (n 21), 8 lesions (38%) had FFR <
28 3/25/2013 Using FFR to Guide S.B. Treatment The best available data shows that there is discordance between the functional significance and the conventional morphologic stenosis severity measured by QCA. FFR is a lesion-specific parameter that can measure the functional significance of a stenotic lesion AND may be useful in the decision to treat a jailed side branch lesion. SB FFR 0.78 Repeat FFR 0.94 Post SB PCI 17
29 3/25/2013 Closing Thoughts IVUS and FFR can (and should) be used to guide the treatment strategy in complex CAD. 18
30 3/25/2013 Making the most important Lesion Decision: FFR in Left Main Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology University California Irvine Orange, California Disclosure: Morton J. Kern, MD Within the past 12 months, the presenter or their spouse/partner have had a financial interest/arrangement or affiliation with the organization listed below. Company Name St. Jude Medical Inc. Volcano Therapeutics Merrit Medical Inc. Opsens Relationship Speakers Bureau Speakers Bureau Consultant Consultant 79 yo M ESRD pre op for renal tx. Asymptomatic LAO RAO 1
31 3/25/2013 LAO caudal RAO caudal FFR=0.94 IVUS FFR=0.94 2
32 3/25/2013 Assessment of LM by FFR- When? Equivocal or Intermediate LM Stenoses Caveat: LM + LAD/CFX involvement is special case, Courtesy of Bernard De Bruyne Technical Notes on FFR for LM assessment 1. Equilibrate wire and guide pressure in aorta, not LM 2. Advance wire across lesion(s) 3. Unseat guide from ostium 4. Use IV adenosine (140mcg/kg/min) FFR CFX with Pull back to ostium CFX wire position ostial wire position 3
33 % Survival 3/25/2013 FFR in Ramus Wire in Ramus FFR in LAD Wire in LAD FFR Criteria for INTERMEDIATE LEFT MAIN CORONARY DISEASE Medical Therapy Surgical Therapy Study FFR Threshold N N (%) MACE Death n(%) MACE Death Follow-up Time (mo) Hamilos (2009) (65%) 26% 9(6.5%) 73 (35%) 17% 7 (9.6%) 35 ± 25 Courtis (2009) 0.75 surg 0.8 med (58%) 13% 3 (3.6%) 60 (42%) 7% 3 (5%) 14 ± 11 Lindstraedt (2006) 0.75 surg 0.8 med (47%) 31% 0 27 (53%) 34% 5(19%) 29 ± 16 Suemaru (2005) (53%) (47%) 29% 0 33 ± 10 Legutko (2005) (53%) 10% 0 18 (46%) 11% 2 24 (mean) Jimenez-Navaro (74%) 10% 0 7 (26%) 29% 2 2 ± 12 Bech (2001) (44%) 24% 0 30 (56%) 17% 1 29 ± 15 Source: Lokhandwala, Juzar MD ; Hodgson, John MD, Cardiac Interventions Today/ October 2009 Clinical Outcome Data after FFR-Guided Revascularization in Patients with LM Equivocal LM Stenosis SURVIVAL RATE All LM Stenoses 100 Pure LM Stenoses p=0.19 FFR 0.80 FFR<0.80 FFR 0.80 No CABG FFR <0.80 CABG FFR 0.80 No CABG 20 FFR <0.80 CABG Months No at risk FFR FFR<
34 3/25/2013 Correlation Between MLA and FFR Kang, S.-J. et al. J Am Coll Cardiol Intv 2011;4: A, Correlation between IVUS MLD and FFR (r=0.79, P Jasti, V. et al. Circulation 2004;110: Assessment of the LM 63 yo M w recent CP, 2y of fatigue. Cath % RCA, 50% LAD, 50% CFX with collaterals to RCA. Normal LV function. LM now significant? 5
35 3/25/2013 Normalized inside guide FFR across LAD ostium FFR across CFX, transient HB 1. FFR OK 2. FFR OK, check both LAD and CFX 3. FFR LM? FALSE Positive (<0.80). Distal Lesion reduces bed. Apply if LAD+LM FFR < FFR LM? FALSE Negative (>0.80). Distal lesions blocks max hyperemia. Go to #3 6
36 3/25/2013 Take Home Points Left Main Angiography not a good standard for determining significance FFR assessment is a direct assessment of physiologic significance Make sure guide catheter pressure waveform no damped (may need to disengage) Use IV adenosine for hyperemia FFR for LM Decisions Improves Outcomes and Appropriateness FFR is in-lab marker of specific ischemic lesion. FFR Reduces Uncertainty If you re not using FFR Retool or Retire 7
37 3/25/2013 Is FFR, IVUS, or OCT the Right Tool in Acute Coronary Syndromes? Intravascular Imaging in ACS Monday, March 25 th,, 2013 Habib Samady MD FACC Professor of Medicine Director, Interventional Cardiology and Cardiac Cath Lab Emory University Hospital, Atlanta, Georgia FFR, IVUS, or OCT in Acute Coronary Syndromes Non-Culprit Culprit Acute < 1 day Sub-acute 1-3 days Timeline Chronic > 7days FFR, IVUS, or OCT in Acute Coronary Syndromes Culprit Acute < 1 day Sub-acute 1-3 days Timeline Chronic > 7days 1
38 3/25/2013 Is FFR, IVUS, or OCT the Right Adjunct To Angiography to Assess Culprit Lesion in Acute Phase of ACS? Any doubt about culprit lesion location? Any doubt about culprit lesion severity? Any relevant questions about culprit lesion morphology? Does everyone receive thrombectomy? In STEMI? How about NSTEMI? Does anyone receive a distal protection device? How well have we reperfused the myocardium? What is the microvascular status? What is the likelihood of functional recovery versus remodeling? Case 1: Inferior STEMI 73 yr old male Dyslipidemia HTN 2 hrs of severe central chest pain HR 100 BP 140/83 + S4, no CHF Culprit Lesion Location, Severity, Morphology in ACS? Stent or no stent? Stent where? 2
39 3/25/2013 Ongoing Chest Pain What is the Culprit Lesion? Stent or no stent? Stent where? MLA 5.5 mm 2 MLA 4.3 mm 2 MLA 2.6 mm 2 OCT Plaque Rupture IVUS Thrombus 3
40 3/25/2013 OCT for Assessing Underlying Lesion Morphology in ACS cap cavity thrombus Plaque Rupture Plaque Erosion Courtesy of Dr. Giulio Guagliumi Courtesy Dr. Ryan Madder 4
41 3/25/2013 Is FFR, IVUS, or OCT the Right Adjunct To Angiography to Assess Culprit Lesion in Acute Phase of ACS? Any doubt about culprit lesion location? OCT Any doubt about culprit lesion severity? OCT/IVUS Questions about culprit lesion morphology? OCT/NIRS Does everyone receive thrombectomy? In STEMI? Mostly How about NSTEMI? Occasionally? OCT Does anyone receive a distal protection device? Currently rarely.? NIRS/OCT/VH How well is myocardium reperfused? What is status of microvascular? What is likelihood of functional recovery versus remodeling? ST resolution, angiographic blush scores, IMR, HMR, MCE, CMR. FFR, IVUS, or OCT in Acute Coronary Syndromes Culprit Acute < 1 day Sub-acute 1-3 days Timeline Chronic > 7days Case: FFR for Assessment Of Culprit Lesions in STEMI subacute reperfused phase 67-year-old was transferred in from an outside facility for anterior STEMI after thrombolytics 5
42 3/25/2013 Right Coronary Artery Left Coronary Artery FFR in Culprit Lesions: Subacute Setting Flow = Pressure Gradient / Resistance Normal microvasculature Recently Infarcted microvasculature Cell death Edema Reperfusion injury Microembolism Vasospasm Is flow proportional to pressure in recently infarcted microvasculature? 6
43 3/25/2013 Validation of FFR in Recent MI N=48 after stabilized STEMI and NSTEMI, underwent SPECT, MCE, FFR, PCI, f/uspect Specificity Sensitivity Figure 6 Samady et al. JACC 2006 FAME Trial: Substudy: ACS versus Stable Angina ACS, FFR, N= 150 ACS, Angio, N=178 Data suggest that like the overall population, a 30% reduction in MACE when FFR is used to guide revascularization in ACS Sels et a. JACC Intv. 2011;4:
44 3/25/2013 Position of MLA in relation to Plaque Rupture not necessarily coincident: prox or distal Plaque Rupture MLA site Proximal Reference Courtesy of Dr. Giulio Guagliumi Is FFR, IVUS, or OCT the Right Adjunct To Angiography to Assess Culprit Lesion in Subacute Phase of ACS? Any doubt about culprit lesion severity? FFR (if there is TIMI 3 flow) particularly for stabilized NSTEMI Questions about culprit lesion location or morphology? OCT 8
45 3/25/2013 FFR, IVUS, or OCT in Acute Coronary Syndromes Non-Culprit Acute < 1 day Sub-acute 1-3 days Timeline Chronic > 7days FFR in Non-Culprit Bed Acute Setting N=101 patients undergoing PCI for AMI (75 STEMI and 26 N-STEMI) N= 112 lesions FFR of non-culprit lesions was measured at time of culprit vessel PCI and repeated 35+4 days later In a subgroup of 14 patients, IMR was also measured at time of culprit vessel PCI and repeated 35+4 days later Ntalianis et al. JACC Int. Volume 3, Issue 12, December 2010, Pages FFR in Non-Culprit Bed Acute Setting Acute Phase (n = 101) Follow-Up (n = 101) p Value LVEF (%) 59 ± ± 14 NS LVEDP (mm Hg) 18 ± 7 17 ± 7 NS FFR nonculprit 0.77 ± ± 0.13 NS IMR nonculprit (IU) 20 ± 3 24 ± 6 NS DS nonculprit (%) 56 ± ± 14 NS MLD nonculprit (mm) 1.32 ± ± 0.50 NS RD nonculprit (mm) 2.9 ± ± 0.70 NS TIMI flow nonculprit 2.93 ± ± 0.20 NS ctfc nonculprit 15 ± 6 15 ± 6 NS Values are mean ± SD. ctfc = corrected TIMI frame count; DS = diameter of stenosis; FFR = fractional flow reserve; IMR = index of microcirculatory resistance; LVEDP = left ventricular end-diastolic pressure; LVEF = left ventricular ejection fraction; MLD = minimum lumen diameter; RD = reference diameter. Ntalianis et al. JACC Int. Volume 3, Issue 12, December 2010, Pages
46 3/25/2013 FFR, IVUS, or OCT in Acute Coronary Syndromes Non-Culprit Acute < 1 day Sub-acute 1-3 days Timeline Chronic > 7days FAME Trial: Substudy: ACS versus Stable Angina ACS, FFR, N= 150 ACS, Angio, N=178 Data suggest that like the overall population, a 30% reduction in MACE when FFR is used to guide revascularization in ACS Sels et a. JACC Intv. 2011;4: FFR, IVUS, or OCT in Acute Coronary Syndromes No use for FFR Culprit OCT, IVUS, NIRS, VH can help identify culprit lesion location, severity, morphology to guide PCI IMR, HMR, CME, CMR can predict functional recovery and remodeling to potentially guide adjunctive pharmacologic or cell therapy Acute < 1 day Sub-acute 1-3 days Timeline Chronic > 7days 10
47 3/25/2013 FFR, IVUS, or OCT in Acute Coronary Syndromes FFR < 0.78 shown to be predictive of ischemia on SPECT and MCE in stabilized reperfused STEMI and NSTEMI Culprit FAME data in stabilized USA/NSTEMI Suggest effective role for FFR in this setting as adjunct to angiography Can use OCT, IVUS NIRS, VH to identify culprit lesion location, severity, morphology to guide PCI Acute < 1 day Sub-acute 1-3 days Timeline Chronic > 7days FFR, IVUS, or OCT in Acute Coronary Syndromes FFR < 0.80 shown to accurately reflect lesion severity IMR also shown to be relatively preserved lending support for FFR s accuracy in this setting Because PCI not recommended for non culprit lesions would avoid other intravascular imaging except to help identify culprit lesion when in doubt Non-Culprit Acute < 1 day Sub-acute 1-3 days Timeline Chronic > 7days FFR, IVUS, or OCT in Acute Coronary Syndromes FFR < 0.80 may be superior to angiography for guiding revascularization of non culprit lesions in stabilized USA/NSTEMI Non-Culprit OCT and IVUS are not ideal for assessment of non culprit lesion severity but may be helpful for optimal stent deployment Acute < 1 day Sub-acute 1-3 days Timeline Chronic > 7days 11
48 3/25/2013 Is FFR, IVUS, or OCT the Right Tool in Acute Coronary Syndromes? Intravascular Imaging in ACS Monday, March 25 th,, 2013 Habib Samady MD FACC Professor of Medicine Director, Interventional Cardiology and Cardiac Cath Lab Emory University Hospital, Atlanta, Georgia 12
49 Using Fractional Flow Reserve to Aid in Decision Making in Tandem Lesions The FFR Pullback William M. Suh, MD Assistant Clinical Professor Ronald Reagan UCLA Medical Center David Geffen School of Medicine at UCLA Financial Disclosures: None Case 63 yo man presents with acute onset dyspnea which awoke him from sleep. Associated with racing heart beat. No angina, orthopnea, PND, edema. PMHx: Dx d with Hyperlipidemia in his 20s, but has not taken anti-hyperlipidemic therapy due to multiple reported intolerances (atorvastatin - palpitations, simvastatin - transaminitis, niacin - transaminitis). 1
50 ECG Labs Biomarkers: CK-MB Negative Troponin <0.01 NT-BNP 2026 Lipids: TC 375 HDL 37 LDL 312 TG 129 Echo Echocardiogram: EF 20% with diffuse hypokinesis Trace AI, mild MR, moderate TR RVSP 40 mmhg RV dilated, RV hypokinesis 2
51 3
52 ??? Stent the mid RCA, ostial RCA, or both? 4
53 FFR of Two Lesions in Series How to Predict FFR of Individual Lesion [FFR predicted = (P d -[(P m /P a )*P w ])/((P a -P m )+(P d -P w )) This calculation requires pressure distal (Pd), pressure proximal (Pa), pressure between lesions (Pm), and coronary occlusion wedge pressure (Pw). Shown in animal models, but impractical for clinical use. How to Perform FFR Pullback Step 1 Position pressure wire with the sensor past the most distal lesion Perform standard FFR with IV adenosine at 140 mcg/kg/min If FFR > 0.80, no treatment is necessary If FFR < 0.80, move to step 2 5
54 How to Perform FFR Pullback Step 2 With IV adenosine still being infused, pullback the pressure wire until the sensor is proximal to the distal lesion. Note the change in pressure (DP). Continue pullback for each lesion again noting the DP Treat the lesion with the largest DP How to Perform FFR Pullback Step 3 After stenting the most severely narrowed lesion, repeat FFR of the remaining lesions. Repeat step 1 and step 2. Pressure sensor 6
55 IV adenosine 140 mcg/kg/min Sensor pullback between lesions, FFR 0.94 Pullback into guide, FFR 1.0 Maximal hyperemia What does this mean? The FFR of both lesions in sum is physiologically significant with FFR 0.64 The largest DP was across the mid RCA lesion indicating that this lesion is the more stenotic of the two The value of 0.94 between the ostial lesion and the mid lesion does not necessarily mean that the ostial lesion is not significant Pijls and DeBruyne demonstrated in an animal model the effect of increasing the severity of the distal lesion on the serial FFR measurements of a proximal lesion in series. As the distal lesion becomes more severe with a larger gradient, the hyperemic flow across the first lesion becomes less and the FFR of the proximal lesion goes up (i.e., becomes less severe). FFR of the ostial lesion needs to be repeated after mid RCA stenting Repeat FFR after mid RCA stent
56 Conclusions In tandem lesions, FFR pullback has the spatial resolution to be able to determine specifically where DP is the largest FFR pullback is a useful tool in assisting decision making in complex coronary lesions and can simplify revascularization strategies. In minimizing unnecessary PCI, immediate and late complications of stenting can be avoided. 8
Benefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationFractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center
Fractional Flow Reserve: Basics, FAME 1, FAME 2 William F. Fearon, MD Associate Professor Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research grant from St. Jude
More informationControversies in Coronary Revascularization. Atlanta CCU April 15, 2016
Controversies in Coronary Revascularization Atlanta CCU April 15, 2016 Habib Samady MD FACC FSCAI Professor of Medicine Director, Interventional Cardiology, Emory University Director, Cardiac Catheterization
More informationCoronary stenting: the appropriate use of FFR
Coronary stenting: the appropriate use of FFR Morton J. Kern, MD Professor of Medicine Chief of Cardiology LBVA Associate Chief Cardiology University California Irvine Orange, California To treat or not
More informationFFR in Left Main Disease
FFR in Left Main Disease William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Why FFR instead of IVUS? Physiologic versus anatomic
More informationFRACTIONAL FLOW RESERVE: STANDARD OF CARE
FRACTIONAL FLOW RESERVE: FROM INVESTIGATIONAL TOOL TO STANDARD OF CARE TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands FRACTIONAL FLOW
More informationPCIs on Intermediate Lesions NCDR Cath-PCI Registry
Practical Application Of Coronary Physiology in The Cath Lab Talal T Attar, MD, MBA, FACC PCIs on Intermediate Lesions NCDR Cath-PCI Registry Fraction of stenoses 50-70% treated with PCI without further
More informationFractional Flow Reserve: Review of the latest data
Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most
More informationCost-Effectiveness of Fractional Flow Reserve
Cost-Effectiveness of Fractional Flow Reserve William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Cost-Effectiveness of FFR What
More informationBifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
More informationEvaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013
Evaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013 Disclosures Consultant- St Jude Medical Boston Scientific Speaker- Volcano Corporation Heart
More informationFFR-Guided PCI. 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea. Stanford
4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea FFR-Guided PCI William F. Fearon, M.D. Associate Professor Division of Cardiovascular Medicine University Medical Center Disclosure Statement
More informationFFR and intravascular imaging, which of which?
FFR and intravascular imaging, which of which? Ayman Khairy MD, PhD, FESC Associate professor of Cardiovascular Medicine Vice Director of Assiut University Hospitals Assiut, Egypt Diagnostic assessment
More informationFFR Incorporating & Expanding it s use in Clinical Practice
FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel
More informationROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE
ROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE Angioplasty Summit TCT ASIA Seoul, Korea, april 24th, 2008 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands A rather common
More informationFRACTIONAL FLOW RESERVE USE IN THE CATH LAB BECAUSE ANGIOGRAPHY ALONE IS NOT ENOUGH!!!!!!!!
FRACTIONAL FLOW RESERVE USE IN THE CATH LAB BECAUSE ANGIOGRAPHY ALONE IS NOT ENOUGH!!!!!!!! Juan Antonio Pastor-Cervantes,M.D FSCAI, FACC Cardiovascular Institute Memorial Regional Hospital Hollywood Florida
More informationFractional Flow Reserve. A physiological approach to guide complex interventions
Fractional Flow Reserve A physiological approach to guide complex interventions What is FFR? Fractional Flow Reserve (FFR) is a lesion specific, physiological index determining the hemodynamic severity
More informationBetween Coronary Angiography and Fractional Flow Reserve
Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve Seung-Jung Park, MD., PhD. University of Ulsan, College of Medicine Asan Medical Center, Seoul, Korea Visual - Functional
More informationSide Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
More informationIntervention: How and to which extent is technology helping us?
Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction
More informationIVUS vs FFR Debate: IVUS-Guided PCI
IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement
More informationIntegrated Use of IVUS and FFR for LM Stenting
Integrated Use of IVUS and FFR for LM Stenting Gary S. Mintz, MD Cardiovascular Research Foundation Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease Fisher
More informationCLINICAL CONSEQUENCES OF THE
CLINICAL CONSEQUENCES OF THE FAME STUDY TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands GUIDELINES ESC SEPTEMBER 2010 FFR UPGRADED TO LEVEL
More informationThe Future of Coronary Physiology
The Future of Coronary Physiology Morton J. Kern, MD Chief of Medicine, VA Long Beach HCS Professor of Medicine University California Irvine Orange, California Disclosure: Morton J. Kern, MD Within the
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationManagement of stable CAD FFR guided therapy: the new gold standard
Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC Should patients
More informationDebate Should we use FFR? I will say NO.
Debate Should we use FFR? I will say NO. Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol Gwon Research fund from Abbott Korea
More informationInstantaneous Wave-Free Ratio
Instantaneous Wave-Free Ratio Alejandro Aquino MD Interventional Cardiology Fellow Washington University in St. Louis Barnes-Jewish Hospital Instantaneous Wave-Free Ratio Alejandro Aquino MD Disclosure
More informationTechnical Aspects and Clinical Indications of FFR
Technical Aspects and Clinical Indications of FFR Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst - OLV Clinic Aalst, Belgium Potential conflicts of interest Consulting fees and honoraria on
More informationFFR in Multivessel Disease
FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands
More informationPost PCI functional testing and imaging: case based lessons from FFR React
Post PCI functional testing and imaging: case based lessons from FFR React Joost Daemen, MD, PhD, FESC Optics in Cardiology 2018 April 21st, 2018 10.15 10.30h Disclosure Statement of Financial Interest
More informationLeft Main Intervention: Will it become standard of care?
Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,
More informationFractional Flow Reserve and the Results of the FAME Study
Imaging and Physiology Summit Seoul, Korea November 21 st, 2009 Fractional Flow Reserve and the Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine
More informationIntegrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes. Gary S. Mintz, MD Cardiovascular Research Foundation
Integrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes Gary S. Mintz, MD Cardiovascular Research Foundation COURAGE Nuclear Substudy (n=314) Death/MI according the residual ischemia (SPECT)
More informationEBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb
EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb A. Medina Servicio de Cardiología Hospital Universitario de Gran Canaria Dr. Negrín Islas Canarias (Spain) Provisional
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationClinical case in perspective. Cases from Poland
Clinical case in perspective Cases from Poland Assoc. Prof. Jacek Legutko, MD, PhD President-Elect of the Association for Percutaneous Cardiovascular Interventions of the Polish Cardiac Society Institute
More informationDave Kettles, St Dominics Hospital East London.
Dave Kettles, St Dominics Hospital East London. 110 x 150 Angina for a couple of months Trop T negative T wave inversion across the chest leads Not wanting to risk radial Huge struggle with femoral
More informationNew Insight about FFR and IVUS MLA
New Insight about FFR and IVUS MLA Can IVUS MLA Predict FFR
More informationPrognostic Value of Gated Myocardial Perfusion SPECT
Current Use of IVUS & FFR George D. Dangas, MD, PhD, FACC, FSCAI Professor of Medicine Mount Sinai School of Medicine Prognostic Value of Gated Myocardial Perfusion SPECT 0.6% / year, Cardiac Death and
More informationFFR= Qs/Qn. Ohm s law R= P/Q Q=P/R
32 ο Πανελλήνιο Καρδιολογικό Συνζδριο, Θεσσαλονίκη 20/10/2011 Gould KL et al, JACC CARDIOVASC IMAG 2009 Gould KL et al AM J CARDIOL 1974 & JACC CARDIOVASC IMAG 2009 Under maximal hyperemia: Rs=Rn FFR=
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationFocus on Acute Coronary Syndromes
Focus on Acute Coronary Syndromes Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Potential conflicts of interest Consulting fees and honoraria on my behalf go to the Cardiovascular
More informationFFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium
FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Conflict of Interest Institutional research grants and speaker s fee from St. Jude Medical and Boston Scientic to Cardiovascular
More informationSTENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
More informationFRACTIONAL FLOW RESERVE Step-by-step measurement, Practical tips & Pitfalls
FRACTIONAL FLOW RESERVE Step-by-step measurement, Practical tips & Pitfalls Ahmed M ElGuindy, MSc, MRCP(UK) Division of Cardiology Aswan Heart Centre 2013 Fractional Flow Reserve Essential diagnostic tool
More informationWhy I try to avoid side branch dilatation
Why I try to avoid side branch dilatation Hyeon-Cheol Gwon Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Why I don t kiss? I kiss! I prefer to discuss SB ballooning rather
More informationLeft Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
More informationFFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT
FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT01724957 Dobrin Vassilev MD, PhD Assoc. Prof. in Cardiology Head Cardiology Clinic, Alexandrovska University Hospital Medical
More informationLe# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
More informationBlinded Physiological Assessment of Residual Ischemia after Successful Angiographic PCI Allen Jeremias, MD, MSc
Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic PCI Allen Jeremias, MD, MSc On behalf of Justin Davies, Manesh Patel, Gregg Stone and the DEFINE PCI Investigators Disclosure
More informationCase Review: Borderline LM with IVUS and FFR. Ravi Ramana, DO Heart Care Centers of Illinois SCAI Annual Conference 2010
Case Review: Borderline LM with IVUS and FFR Ravi Ramana, DO Heart Care Centers of Illinois SCAI Annual Conference 2010 Disclosures No relevant disclosures. Borderline Left Main Disease Significant LMS
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationLeft Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD
Left Main PCI Integrated Use of IVUS and FFR Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea Efficacy of Left
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationFractional Flow Reserve (FFR) --Practical Set Up Pressure Measurement --
Fractional Flow Reserve (FFR) --Practical Set Up Pressure Measurement -- JoonHyung Doh, MD, PhD Assistant Professor, Vision21 Cardiac and Vascular Center Inje University Ilsan Paik Hospital Goyang, Korea
More informationCan We Safely Defer PCI. Yes, already proven
Can We Safely Defer PCI Just Based on FFR>0.80? Yes, already proven Seung-Jung Park, MD., PhD. Professor of Medicine, University of Ulsan, College of Medicine Heart Institute, Asan Medical Center, Seoul,
More informationAnatomical, physiological and clinical relevance of a side branch
Anatomical, physiological and clinical relevance of a side branch : Which branch really needs a stent? Bon-Kwon Koo, MD, PhD, Seoul, Korea Bifurcation lesion: The GREAT EQUALIZER! No intervention = Balloon
More informationFFR-guided Jailed Side Branch Intervention
FFR-guided Jailed Side Branch Intervention - Pressure wire in Bifurcation lesions - Bon-Kwon Koo, MD, PhD Seoul National University Hospital, Seoul, Korea Bifurcation Lesions Bifurcation Lesions Still
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationOCT guidance for distal LM lesions
OCT guidance for distal LM lesions FRANCESCO BURZOTTA INSTITUTE OF CARDIOLOGY CATHOLIC UNIVERSITY OF THE SACRED HEART ROME, ITALY LM suitability for OCT At FU in stented LM Parodi G et al. Eurointervention
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More informationAssessing Myocardium at Risk: Applying SYNTAX
Assessing Myocardium at Risk: Applying SYNTAX Farouc Jaffer MD PhD FSCAI FACC FAHA Associate Professor of Medicine, Harvard Medical School Director, CAD Program and Chronic Total Occlusion PCI Program
More informationJose Mª de la Torre Hernandez, MD, PhD, FESC. Cardiologia Valdecilla Hospital Universitario Marques de Valdecilla Santander. SPAIN
Validation and application of IVUS-MLA in LMCA disease Jose Mª de la Torre Hernandez, MD, PhD, FESC Interventional Cardiology Dpt Cardiologia Valdecilla Hospital Universitario Marques de Valdecilla Santander.
More information8 th European Bifurcation Club October Barcelona
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Jose Mª de la Torre Hernandez, MD, PhD, FESC Interventional Cardiology Dpt Cardiologia Valdecilla Hospital Universitario Marques de Valdecilla
More informationFractional Flow Reserve and the 1 Year Results of the FAME Study
Imaging and Physiology Summit Seoul, Korea, November 22, 2008 Fractional Flow Reserve and the 1 Year Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine
More informationΣεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική
ΕΛΛΗΝΙΚΗΚΑΡΔΙΟΛΟΓΙΚΗΕΤΑΙΡΕΙΑ Σεμινάριο Ομάδων Εργασίας 2011 Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική GUIDELINES ON MYOCARDIAL
More informationDiffuse Disease and Serial Stenoses. Bernard De Bruyne Cardiovascular Center Aalst Belgium
Diffuse Disease and Serial Stenoses Bernard De Bruyne Cardiovascular Center Aalst Belgium Atherosclerosis is a Diffuse Disease Serial Stenoses A B P a P m P d When A is isolated, hyperemic flow through
More informationPlaque Shift vs. Carina Shift Prevalence and Implication
TCTAP 2013 Fellowship Course Left Main and Bifurcation PCI: Bifurcation PCI Plaque Shift vs. Carina Shift Prevalence and Implication Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan
More informationFFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators
FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of
More informationFinal Kissing Ballooning Returns? The analysis of COBIS II registry
Final Kissing Ballooning Returns? The analysis of COBIS II registry Hyeon- Cheol Gwon Heart Vascular & Stroke Ins?tute, Samsung Medical Center Sungkyunkwan University School of Medicine Final Kissing Ballooning
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationComplex PCI of an LAD/Diagonal bifurcation lesion (Medina 1,1,1) utilizing the DK Crush technique ".
Complex PCI of an LAD/Diagonal bifurcation lesion (Medina 1,1,1) utilizing the DK Crush technique ". "Σύμπλοκη αγγειοπλαστική βλάβης διχασμού LAD/Diagonal (Medina 1,1,1) με την τεχνική DK crush ". Anastasios
More informationCardiovascular Research Foundation and Columbia University Medical Center, New York.
Virtual Histology Intravascular Ultrasound Analysis of Non-culprit Attenuated Plaques Detected by Grayscale Intravascular Ultrasound in Patients with Acute Coronary Syndromes Xiaofan Wu, Akiko Maehara,
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationComplex Coronary Interventions: Bifurcations. John M. Lasala MD PhD Professor of Medicine Washington University St Louis, Missouri
Complex Coronary Interventions: Bifurcations John M. Lasala MD PhD Professor of Medicine Washington University St Louis, Missouri Disclosures Advisory Board Boston Scientific, St. Jude Medical Speaker-
More informationFFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results. Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria
FFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria I would like to express my personal gratitude to Dr. BK Koo for opening
More informationFractional Flow Reserve (FFR) --Practical Set Up Pressure Measurement --
Fractional Flow Reserve (FFR) --Practical Set Up Pressure Measurement -- Joon Hyung Doh, MD, PhD Associate Professor, Division of Cardiology Inje University Ilsan Paik Hospital Goyang, Korea 목차 Fractional
More informationFractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease. FAME 2 Trial
Fractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease FAME 2 Trial Clinicaltrials.gov NCT01132495 Bernard De Bruyne, Nico H.J. Pijls, William F Fearon, Peter Juni, Emanuele
More informationDo stents deserve the bad press? Mark A. Tulli MD, FACC
Do stents deserve the bad press? Mark A. Tulli MD, FACC Disclosures: None Introduction Stents don t help people. Stents are bad for patients. Heart Treatment Overused WSJ Study Finds Doctors Often Too
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationIVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.
Left Main and Bifurcation Summit IVUS-Guided d Provisional i Stenting: ti Plaque or Carina Shift Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan College of Medicine Asan Medical Center,
More informationMid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationFAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS
Coronary Physiology In The Cathlab FAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS Educational Training Program ESC European Heart House april 7th 9th 2011 Nico H.J.Pijls, MD, PhD Catharina Hospital,
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationDiffuse Disease and Serial Stenoses
Diffuse Disease and Serial Stenoses Bernard De Bruyne Cardiovascular Center Aalst Belgium Atherosclerosis is a Diffuse Disease Serial Stenoses A B P a P m P d When A is isolated, hyperemic flow through
More informationFFR: Tips and Tricks. A/Prof (Adj) Yeo Khung Keong, MBBS, FAMS, FACC, FSCAI National Heart Centre Singapore
FFR: Tips and Tricks A/Prof (Adj) Yeo Khung Keong, MBBS, FAMS, FACC, FSCAI National Heart Centre Singapore Disclosures Abbott Vascular: Speaker, Proctor (MitraClip) Boston Scientific: Consultant, honorarium
More informationOCT Findings: Lesson from Stable vs Unstable Plaques
ANGIOPLASTY SUMMIT TCTAP 2010 Imaging Workshop OCT Findings: Lesson from Stable vs Unstable Plaques Giulio Guagliumi MD Ospedali Riuniti di Bergamo, Italy DISCLOSURE OF FINANCIAL INTERESTS Consultant Boston
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More information